Skip to main content
. 2022 Oct 10;13:5959. doi: 10.1038/s41467-022-33555-8

Fig. 5. Identification of transcriptomic signatures associated with a high risk of recurrence and poor prognosis.

Fig. 5

a Discovery of the STRAC11 GES [derived from the sunitinib-treated S-TRAC trial population] according to bootstrapping frequency. Kaplan–Meier plot of b differential DFS probability by STRAC11 in the S-TRAC placebo arm and c sunitinib arm. Kaplan–Meier plot of differential d PFS probability and e OS probability by STRAC11 in the TCGA data set; f differential PFS by STRAC11 in the JAVELIN Renal 101 overall population data set and g by treatment arm. AMT aminomethyltransferase, APOBEC3A apolipoprotein B mRNA editing enzyme catalytic subunit 3A, ARRDC1 arrestin domain-containing 1, CI confidence interval, DFS disease-free survival, HR hazard ratio, MERTK MER tyrosine kinase, MROH8 maestro heat like repeat family member 8, NE not estimable, PRKAB1 protein kinase AMP-activated non-catalytic subunit beta 1, SLC16A1 solute carrier family 16, member 1, SLPI secretory leukocyte peptidase inhibitor, SNX29 sorting nexin 29, STEAP1 six transmembrane epithelial antigen of the prostate family member 1, TCGA The Cancer Genome Atlas, TDO2 tryptophan 2,3-dioxygenase.